The invention provides novel nicotinic acetylcholine receptor agonists, for example, phaiitasmidine and derivatives thereof, for example a compound of formula (I). Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acet lcholine rece tor a onists.
NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS